A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. 
C
hronic myeloid leukemia (CML) syndromes in humans are phenotypically characterized by leukocytosis with normal maturation and differentiation of myeloid lineage cells. Cloning of recurring chromosomal translocations associated with the CML phenotype has invariably identified constitutively activated tyrosine kinases that are expressed as a consequence of the translocation. The most common of these is the t(9;22)(q34;q22) associated with the BCR͞ABL fusion transcript (1) . Other examples include the t(5;12)(q33;p13), t(9;12)(q34;p13), t(9;12)(p24;p13), and t(5;10)(q33;q11.2) translocations associated with the TEL͞ PDGF␤R (2) , TEL͞ABL (3), TEL͞JAK2 (4), and H4͞PDGF␤R (5, 6) fusions, respectively. Expression of these constitutively activated tyrosine kinases in a murine bone marrow transplantation assay system is both necessary and sufficient to cause a myeloproliferative disease in animals that has many of the features of CML in humans (7) (8) (9) . The phenotype includes leukocytosis, splenomegaly, and extramedullary hematopoiesis with normal maturation and differentiation of myeloid lineage cells. Transformation is dependent on kinase activity, as demonstrated by point mutations that abrogate kinase activity, as well as by ABL and PDGF␤R kinase-specific inhibitors in vitro and in vivo (8, (10) (11) (12) (13) (14) (15) .
In contrast to chronic myeloid leukemias, cloning of recurrent chromosomal translocation breakpoints in acute leukemias has identified fusion genes that encode transcription factors or transcription regulatory proteins such as CBFB͞MYH11 (16) , PML͞ RAR (17) , MLL͞CBP (18) , MLL͞ENL (19) or NUP98͞HOXA9 (20, 21) . Expression of certain of these transcription factor fusions in murine bone marrow transplantation assays or transgenic systems may result in acute myeloid leukemia after latency of 6-12 months, indicating a requirement for additional cooperating mutations. Although the functional contribution of these fusion proteins to the leukemic phenotype is not completely understood, many impair normal hematopoietic development (22) (23) (24) (25) (26) (27) . In addition, none of the aforementioned fusion genes is sufficient to cause acute leukemia in murine models. We hypothesize that one class of mutations, exemplified by constitutively activated tyrosine kinases in CML, confer a proliferative and͞or survival advantage but do not affect differentiation. A second class of mutations, involving mutations in hematopoietic transcription factors, impairs hematopoietic differentiation.
Disease progression from CML to AML (or CML ''blast crisis'') in patients provides indirect support for this hypothesis. BCR͞ABL-positive CML may progress to AML with the acquisition of either t(7;11)(p15;p15) or t(3;21)(q26;q22) associated with expression of the NUP98͞HOXA9 fusion (20, 21, (28) (29) (30) or the AML1͞EVI1 fusion (31) (32) (33) , respectively. In other examples, progression of t(5;12) CML with the TEL͞PDGFR fusion to A ML may be associated with the acquisition of the t(8;21)(q22;q22) translocation generating the AML1͞ETO fusion protein (2) .
Here we report a murine model of CML blast crisis mediated by a cooperation between BCR͞ABL, a constitutively activated tyrosine kinase, and the NUP98͞HOXA9 fusion. The tumors retain sensitivity to the ABL inhibitor STI571. This model demonstrates that AML although genetically complex, may retain dependence on an initial oncogenic event. This has important implications for the use of tyrosine kinase inhibitors in the therapy of de novo AML.
Materials and Methods
Constructs and Cloning. An EcoRI fragment from pBSNUP98͞ HOXA9 (20) containing the entire coding sequence of the NUP98͞ HOXA9 fusion gene was cloned into the EcoRI site of the retroviral bicistronic expression vector MSCV-IRES-EGFP (a kind gift from W. Pear, University of Pennsylvania, Philadelphia). MSCV-IRES-EGFP without insert was used as a vector control. p210 BCR͞ABL, TEL͞PDGF␤R (8) , and mutSTAT5a (9) were all cloned into the retroviral vector MSCVneo (kindly provided by R. Hawley, Red Cross, Rockville, MD). Viral Supernatants and Bone Marrow Reconstitution Assay. Retroviral supernatants were generated and bone marrow transplants were performed as described (9) , except that retroviral transduction of bone marrow cells was done by spinoculation (34) . Viral titers of the MSCV-NUP98͞HOXA9 or the MSCV-IRES-EGFP viral stocks were determined by assaying for EGFP expression 48 h post transduction by flow cytometry. Equal titers of the MSCV-NUP98͞ This paper was submitted directly (Track II) to the PNAS office.
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HOXA9 or the MSCV-IRES-EGFP viral stocks were used in all of the experiments. The amount of the MSCVneo-BCR͞ABL supernatant used in these experiments was 10% (i.e., 100 l) of the amount (i.e., 1,000 l) that reproducibly caused a short latency rapid myeloproliferative disease in control experiments (data not shown). For the secondary bone marrow transplants, frozen spleen cells from the donor mice were thawed, then specified numbers of viable cells were injected into sublethally irradiated [1 ϫ 450 centigray (cGy)] BALB͞c mice. At least two independent transduction͞transplantation experiments were carried out for each of the combinations of genotypes with similar results, and the data combined to generate the survival curves. Kaplan-Meier survival analyses were performed using the program STATVIEW (SAS Institute, Cary, NC).
DNA Isolation and Southern Analysis. Genomic DNA was isolated from various tissues by using a PUREGENE DNA isolation kit (Gentra Systems, Minneapolis). For analysis of proviral integrations, genomic DNA was digested with XbaI. For assay of clonality, Kaplan-Meier survival analysis of mice that have undergone bone marrow transplantation. Mice transplanted with bone marrow that was transduced with NH alone did not develop disease with Ͼ5 months of follow up (4 mice in cohort). In contrast, bone marrow cotransduced with BCR͞ABL (BA) and NH induced an acute myeloid leukemia with a latency of 21 days (12 mice in cohort). Under these experimental conditions, BA alone induced a myeloproliferative disease with a latency of 5-17 weeks (6 mice in cohort). Viral supernatants were titered to ensure transduction of 10% and 1% of cells by NUP98͞HOXA9 and BCR͞ABL, respectively. Thus, under these conditions only 0.1% of cells would be doubly transduced with both retroviruses. The amount of the MSCVneo-BCR͞ABL supernatant used in the control experiments, as well as the BA͞NH synergy experiments, was 10% of the amount that reproducibly caused a short latency rapid myeloproliferative disease in control mice (data not shown). Animals transduced with NH alone showed splenic morphology typical of posttransplant control mice with a mild degree of extramedullary hematopoiesis at 21 days (c). At 7 months, however (d), myeloid maturation was not seen and a proliferation of myeloid blast forms was present consistent with the development of myeloid leukemia [as has been reported (27) ]. Animals transplanted with marrow transduced with BA (e) or TP (g) alone developed a myeloproliferative disease with varying degrees of myeloid maturation and extensive extramedullary hematopoiesis, particularly in the case of BA. In sharp contrast both BA and TP, when cotransduced with NH ( f and h, respectively), induced a morphologically identical short latency disease demonstrating a myeloid maturation arrest and a sheet-like proliferation of myeloid blast forms, with a diminished degree of extramedullary hematopoiesis. Similarly, bone marrow and liver demonstrated extensive replacement by myeloid blast forms (data not shown). Flow Cytometric Immunophenotyping. Single-cell suspensions from spleen, blood, and bone marrow were prepared as described (9) . Aliquots of 0.5 to 2.0 ϫ 10 6 cells were stained for 20 min on ice with APC-conjugated anti-Gr-1, PE-conjugated anti-Mac-1, PEconjugated anti-CD117, biotin-conjugated anti-CD19, biotinconjugated anti-CD34 (PharMingen), APC-conjugated anti-CD4, or APC-conjugated anti-CD8 (Caltag, South San Francisco, CA). APC-conjugated streptavidin (Caltag) was used as a secondary reagent to detect the binding of the biotinylated primary antibody. Multicolor flow cytometric analysis was done with a FACSort (Becton-Dickinson). A minimum of 10,000 events was acquired and the data were analyzed using CELLQUEST software (Version 3.1, Becton-Dickinson).
Histopathology. Murine tissues were fixed for at least 72 h in 10% neutral buffered formalin (Sigma), dehydrated in alcohol, cleared in xylene, and infiltrated with paraffin. Four-micrometer-thick tissue sections from paraffin embedded tissue blocks were placed on charged slides, deparaffinized in xylene, rehydrated through graded alcohol solutions, and stained with hematoxylin͞eosin. 
Results

BCR͞ABL and NUP98͞HOXA9 Cooperate to Induce an Acute Myeloid
Leukemia. To determine whether NUP98͞HOXA9 cooperated with BCR͞ABL to cause an acute myeloid leukemia, we cotransduced murine bone marrow cells with murine ecotropic retrovi- ruses encoding the BCR͞ABL or NUP98͞HOXA9 fusion genes, respectively. Transduced bone marrow cells were then introduced into syngeneic, lethally irradiated, recipient mice, as described (9) . Bone marrow cells cotransduced with BCR͞ABL and NUP98͞ HOXA9 retrovirus induced an acute myeloid leukemia with a latency of 21 days and with features of myeloid blast crisis of CML ( Fig. 1 a and f ) . The histopathologic features of the leukemia included a myeloid maturation arrest with a concomitant proliferation of myeloid blast cells in the spleen (Fig. 1f ) , liver, and bone marrow (data not shown). We identified these cells as immature myeloid cells displaying the stem cell markers CD34 and CD117 (Fig. 3c) . These cells stained negative for lymphoid markers CD4, CD8, and CD19, confirming their myeloid nature (data not shown). Ten thousand cells obtained from primary recipient mice were transplantable into secondary recipients, and caused a fatal acute myeloid leukemia with a latency of 2 weeks (Fig. 2a) . AML in secondary recipients had a shift toward a more immature phenotype, as shown histopathologically (Fig. 2c) and by flow cytometry as evidenced by increased numbers of CD34 ϩ and CD117 ϩ cells (Fig. 3d) . In control experiments, bone marrow cells were also transduced with retroviruses encoding either fusion gene alone. Under the conditions used for this experiment, BCR͞ABL induced a myeloproliferative disease with a latency of 5-17 weeks and normal myeloid maturation, and comprised predominantly of neutrophils as described (ref. 7; see Fig. 1 a and e) . NUP98͞HOXA9 alone gave an AML phenotype, but with markedly prolonged latencies ( Fig. 1 a and d) . This observation is consistent with previous reports that NUP98͞HOXA9 requires additional mutations to cause AML (27) .
Limiting Dilution Experiments Demonstrate the Requirement for Both
BCR͞ABL and NUP98͞HOXA9 Provirus. Cooperation between the two fusion genes in the generation of AML would predict a selective growth advantage for rare double transductants versus cells transduced with a single retrovirus. Therefore, the cotransduction experiments were designed using low titer retroviral supernatants such that a fraction of bone marrow cells would be transduced with either the BCR͞ABL or the NUP98͞HOXA9 retrovirus, whereas only rare cells would be transduced with both retroviruses. The amount of the MSCVneo-BCR͞ABL supernatant used in these experiments was 10% of the amount that reproducibly caused a short latency rapid myeloproliferative disease in control mice (see Figs. 6-8, which are published as supporting information on the PNAS web site, www.pnas.org). There was purposefully no selection for doubly transduced cells using either flow cytometry or antibiotic selection. Thus, the observation that cotransduction resulted in a short latency acute myeloid leukemia phenotype that was readily distinguishable from the phenotype observed with In limiting dilution experiments, secondary mice received 10 6 , 10 5 , or 10 4 cells from primary donors. Primary disease was oligoclonal in nature, with several independent clones indicated by asterisks, whereas the secondary recipients had either a biclonal or a monoclonal disease. The presence of a single clonal integrant for BA and NH, respectively, at the limit dilution of 10 4 cells demonstrates the requirement for integration of both BA and NH provirus for the acute leukemia phenotype. The large arrow points to the predominant leukemic clone selected for by limit dilution, whereas the small arrow points to additional leukemic clones seen in most of the secondary transplants. Dash Limiting dilution experiments showed that as few as 10 4 cells could recapitulate the blast crisis phenotype in secondary recipient animals, whereas no disease was observed when 10 3 or fewer cells were transplanted (Fig. 2a) . These data indicated that 10 4 cells from primary BMT recipients contained Ϸ1 leukemia repopulating cell. Southern blot analysis was performed with Neo R and EGFP c-DNA probes, respectively, on spleen cells derived from diseased secondary recipient animals. These blots (Fig. 4 d-g ) confirmed that leukemic cells transplanted at limit dilution contained both the BCR͞ABL and NUP98͞HOXA9 proviruses. Furthermore, analysis using restriction enzymes that cleave once within the proviral insert demonstrated monoclonality of these leukemic cells, confirming limit dilution in these assays (Fig. 4 h and i) . Similar analysis of clonal cell lines generated in vitro from the spleens of primary leukemic mice demonstrated that BCR͞ABL and NUP98͞HOXA9 fusion genes were present in the same cell (data not shown). Taken together, these data provide convincing evidence for cooperativity between BCR͞ABL and NUP98͞HOXA9 in a cotransduction system that allows for biological selection for rare doubly transduced murine bone marrow cells.
TEL͞PDGF␤R and NUP98͞HOXA9 also Cooperate to Induce an Acute
Myeloid Leukemia. To determine whether the cooperation between the constitutively activated BCR͞ABL tyrosine kinase and NUP98͞HOXA9 could be generalized to other tyrosine kinase fusions, similar cotransduction experiments were performed using a TEL͞PDGFG␤R retrovirus. TEL͞PDGF␤R cotransduced with NUP98͞HOXA9, using a strategy similar to that described above, also resulted in a myeloid blast crisis phenotype indistinguishable from the BCR͞ABL ϩ NUP98͞HOXA9 phenotype (Figs. 1 b, e, and f, and 2 b and d). These data indicate that the paradigm for cooperation between BCR͞ABL and NUP98͞HOXA9 can be extended to other tyrosine kinase fusion genes.
BCR͞ABL-NUP98͞HOXA9 Leukemic Cells Retain Sensitivity to STI571.
Progression of CML to blast crisis is usually a fatal complication of the disease. There are few effective therapies, and even intensive chemotherapy and allogeneic stem cell transplantation are usually ineffectual. To determine whether cells in the murine model of CML blast crisis remained dependent on the ABL kinase despite acquisition of the additional NUP98͞HOXA9 mutation, we assayed the ability of STI571, an ABL kinase inhibitor of the 2-phenylaminopyrimidine class (35, 36) , to impair growth of BCR͞ABL-NUP98͞ HOXA9 leukemic cells. As shown in Fig. 5a , these cells demonstrated sensitivity to STI571 in methylcellulose colony forming assays. Control experiments demonstrated that cells cotransduced with a constitutively activated mutant of STAT5 (37), which is not inhibited by STI571, and NUP98͞HOXA9 were insensitive to STI571. Ex vivo and in vivo experiments demonstrated that treatment of BA͞NH leukemic cells with STI571 abrogated leukemogenic potential in secondary transplant recipients (Fig. 5 c-e) . AML could be abrogated in animals transplanted with 10 4 BA͞NH leukemic cells treated with STI571 (Fig. 5e ). Growth analysis of the BA͞NH cells in the presence of STI571 confirmed that majority of the BA͞NH leukemic cells were sensitive to STI571 treatment (Fig.  5b) . However, we observed that higher doses of cells treated with STI571 still caused AML in secondary recipients (Fig. 5 c and d) . For example, 10 6 cells transplanted after STI571 treatment were fully capable of inducing AML (Fig. 5c) . Similarly, in the four recipient mice that were first transplanted with BA͞NH leukemic cells and subsequently treated with STI571 by oral gavage, one mouse succumbed to AML, whereas the disease was abrogated in the others (Fig. 5f ).
Discussion
Chronic myelogenous leukemia invariably progresses to acute leukemia, but little is understood about the mechanisms of progression. However, in some cases secondary cytogenetic abnormalities have been identified that are associated with disease progression, including the NUP98͞HOXA9 fusion. We have demonstrated that BCR͞ABL cooperates with NUP98͞ HOXA9 to cause an acute leukemia phenotype in a murine model that recapitulates the essential features of CML blast crisis in humans.
These data support a model in which two mutations are required for acute leukemia phenotypes. One class of mutations, exemplified by BCR͞ABL, confers proliferative and͞or survival advantage to cells but does not affect differentiation. A second class of mutations, exemplified by NUP98͞HOXA9, confers a subtle growth advantage to hematopoietic cells, but serve primarily to impair hematopoietic differentiation. Previous literature has indicated that cooperation between oncogenes may contribute to leukemic phenotypes (38) (39) (40) , but this is the first direct demonstration that two oncogenes associated with progression of human CML to blast crisis cooperate to cause acute leukemia. Furthermore, these experiments indicate that although acute leukemia cells harbor more than one mutation, they retain some level of dependence on BCR͞ABL. Similar conclusions were reached in a tetracycline-regulated murine model of BCR͞ABL disease (41).
In our experiments, BA͞NH leukemia cells retained sensitivity to the ABL inhibitor STI571 in cell culture systems. Pretreatment of BA͞NH cells with1 M STI571 was sufficient to prevent leukemia in secondary recipients that received 1 ϫ 10 4 cells. However, at higher doses of cells treated with the same concentration of STI571 (1 ϫ 10 5 or 1 ϫ 10 6 cells, respectively) AML still developed in secondary recipient mice. We also observed that one-fourth of secondary recipients of BA͞NH cells treated with twice daily oral gavage with STI571 also developed AML. It is possible that BA͞NH cells may have escaped STI571-induced cell death because of pharmacokinetic considerations in these experiments. Alternatively, these cells may have developed STI571 resistance. Further experiments will be required to test these possibilities. It has recently been reported that a significant proportion of CML myeloid blast crisis patients respond to STI571, although resistance and relapse of disease occurs in the majority of responders (42) . Resistance to STI571 has also recently been shown to be associated with BCR͞ABL amplification or point mutations in the kinase domain of BCR͞ABL oncoprotein that impair STI571 binding (43) . The availability of a murine model of CML blast crisis that recapitulates the human response to the drug may provide a useful platform for analysis of mechanisms of resistance to STI571 and to test the efficacy of STI571 in combination with other agents that might circumvent resistance mechanisms. These data also suggest that it may be possible to treat de novo AML with tyrosine kinase inhibitors. Recent data indicates that both FLT3 and c-KIT may be attractive therapeutic targets based on activating mutations in these receptor tyrosine kinases in a significant proportion of AML patients (44) .
